Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood tests may reveal why some cancers resist immunotherapy

NCT ID NCT06075524

First seen Jan 07, 2026 · Last updated May 23, 2026 · Updated 20 times

Summary

This study looks at how immune cells called T cells change in people with advanced melanoma, lung cancer, or other solid tumors during anti-PD-1 treatment. Researchers will measure specific markers in blood samples to see if they can predict whether the therapy is working or if resistance is developing. The goal is to better understand why some patients respond to treatment and others do not. About 500 adults starting or continuing anti-PD-1 therapy will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IV LUNG CANCER AJCC V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.